Delcath Systems Inc. (DCTH) Next Earnings Date & Expected ±7.7% Move

Per the Roarable RQD rating, DCTH scores 62 out of 100, a letter grade of C, labeled "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are: Fundamental Cash Engine at 14 of 20 (ROIC 0.8%; FCF yield 4.13%), Whale 13F Flow at 10 of 20 (institutional accumulation and options positioning), Insider Conviction at 11 of 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 9 of 20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 18 of 20 (Altman Z 20.33; Piotroski F 8/9; Debt/Equity 0.5).

For a prospective investor, the composite reads as balanced rather than decisive. The strongest pillar is the forensic balance sheet, which indicates low solvency concern on the metrics provided. The weakest pillar is macro regime fit, where a Beta of 1.0 means the stock is scored as moving in line with the market and sector sensitivity was rated low-scoring. The fundamental cash engine is moderate: a 0.8% ROIC is thin, although the 4.13% FCF yield provides some support. Upside drivers implied by the scores would include sustained improvement in return on invested capital and continued institutional accumulation; valuation tradeoffs center on the fact that trailing earnings multiples are not available in source data, so the price cannot be assessed against earnings in this dossier.

Delcath Systems Inc. (DCTH) is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry. The profile identifies the company as operating in this sector and industry with a market capitalization of $0.5B. Source data does not describe its specific products, customers, or revenue model. Per the SEC financials, reported revenue grew from $2.1M in FY 2023 to $37.2M in FY 2024 and $85.2M in FY 2025.

Per the SEC financials, the company moved from operating and net losses in FY 2023 and FY 2024 to positive operating and net income in FY 2025. Per the market data, gross margin is 86.2%, operating margin 0.8%, and net margin 3.2%, with ROIC at 0.8%. Per the Roarable RQD rating, the Altman Z-Score is 20.33 and the Piotroski F-Score is 8 of 9, and Debt/Equity is 0.5, indicating a strong forensic balance sheet posture. Debt values are not available in source data.

• Earnings call: A headline references hosting a Third Quarter 2026 earnings call (YELLOW, Market Wire).
• Prior call: A headline references a Q2 2026 earnings call transcript (YELLOW, Market Wire).
• Price action: A headline reports DCTH hit a fresh 52-week high and its best day in nearly 15 months (YELLOW, Market Wire).
• Investor event: A headline references a live webcast of a UBS conference (YELLOW, Market Wire).
• Risk Watch: A headline titled in terms of risk allocation models was flagged RED (Risk Watch), with no further detail in source data.
• Price drift: A headline reports shares slipped 2.24% to $14.42 toward lower support (YELLOW, Market Wire).

Per the Butterfly Supply-Chain Graph, supply chain is NONE, no butterfly links exist, and there are no proprietary signals.

• What are the company's trailing and forward earnings and EPS, given these fields are not available in source data?
• What drove the swing from FY 2024 operating losses to FY 2025 operating income, and is it repeatable?
• What is the debt balance, given Debt is reported as N/A in each period?
• What products and customers generate the reported revenue, and how concentrated is that revenue?
• What is the institutional and insider ownership composition behind the RQD flow pillars?